摘要
目的 观察高病毒载量慢性乙型肝炎患者治疗中替诺福韦酯与恩替卡韦的临床效果。方法 回顾性选取2011年2月—2021年2月黑龙江省大庆市油田总医院高病毒载量慢性乙型肝炎患者60例,依据用药方法分为替诺福韦酯组、恩替卡韦组两组,各30例,统计分析两组实验室指标、ALT复常情况、生物化学应答、病毒学应答情况、临床疗效、满意度。结果 用药前,两组患者的血清HBV DNA、AST、ALT、TBIL水平之间的差异无统计学意义(P>0.05);用药后,两组患者的血清HBV DNA、AST、ALT、TBIL水平均低于用药前,差异有统计学意义(P<0.05),替诺福韦酯组患者的血清HBV DNA、AST、ALT、TBIL水平均低于恩替卡韦组,差异有统计学意义(P<0.05)。替诺福韦酯组患者的6个月、1年ALT复常率均高于恩替卡韦组,差异有统计学意义(P<0.05),但两组患者的1个月、3个月ALT复常率之间的差异无统计学意义(P>0.05)。替诺福韦酯组患者的生物化学应答率、病毒学应答率86.67%(26/30)、93.33%(28/30)均高于恩替卡韦组56.67%(17/30)、60.00%(18/30),差异有统计学意义(P<0.05)。替诺福韦酯组患者的有效率93.33%(28/30)高于恩替卡韦组66.67%(20/30),差异有统计学意义(χ^(2)=6.667,P<0.05)。替诺福韦酯组患者的满意度96.67%(29/30)高于恩替卡韦组73.33%(22/30),差异有统计学意义(χ^(2)=4.706,P<0.05)。结论 高病毒载量慢性乙型肝炎患者治疗中替诺福韦酯的临床效果较恩替卡韦好。
Objective To observe the clinical effect of tenofovir disoproxil and entecavir in the treatment of chronic hepatitis B patients with high viral load.Methods Sixty patients with chronic hepatitis B with high viral load from February 2011 to February 2021 in Daqing Oilfield General Hospital of Heilongjiang Province were retrospectively selected. According to the medication method, they were divided into tenofovir disoproxil group and entecavir group,with 30 cases in each group. Statistical analysis of laboratory indicators, ALT normalization, biochemical response, virological response, clinical efficacy and satisfaction in the two groups were analyzed.Results Before treatment, there was no significant difference in serum HBV DNA, AST, ALT and TBIL levels between the two groups(P>0.05). After treatment, the levels of serum HBV DNA, AST, ALT, and TBIL in the two groups were lower than those before treatment, and the difference was statistically significant(P<0.05). The serum levels of HBV DNA, AST, ALT and TBIL in the tenofovir disoproxil group were lower than those in the entecavir group, and the difference was statistically significant(P<0.05). The 6-month and 1-year ALT normalization rates in the tenofovir disoproxil group were higher than those in the entecavir group, and the difference was statistically significant(P<0.05). However, there was no significant difference in the ALT normalization rate between the two groups at 1 month and 3 months(P>0.05). The biochemical response rate and virological response rate of patients in the tenofovir disoproxil group were 86.67%(26/30)and 93.33%(28/30), higher than the entecavir group by 56.67%(17/30) and 60.00%(18/30), the difference was statistically significant(P<0.05). The effective rate of tenofovir disoproxil group was 93.33%(28/30) higher than that of entecavir group 66.67%(20/30), and the difference was statistically significant(χ^(2)=6.667, P<0.05). The satisfaction rate of patients in the tenofovir disoproxil group was 96.67%(29/30) higher than that in the entecavir group, 73.33%(22/30), and the difference was statistically significant(χ^(2)=4.706, P<0.05).Conclusion The clinical effect of tenofovir disoproxil in the treatment of chronic hepatitis B patients with high viral load is better than that of entecavir.
作者
王辉
WANG Hui(General Department of Daqing Oilfield General Hospital,Daqing,Heilongjiang Province,163000 China)
出处
《系统医学》
2022年第16期100-103,132,共5页
Systems Medicine
